186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)

医学 内科学 肿瘤科 卡培他滨 生活质量(医疗保健) 曲妥珠单抗 耐火材料(行星科学) 拉帕蒂尼 乳腺癌 胃肠病学 癌症 结直肠癌 物理 护理部 天体生物学
作者
Tanja Fehm,F. Cottone,K. Dunton,Fabrice André,Ian E. Krop,Y.H. Park,Michelino De Laurentiis,Yasuo Miyoshi,Anne Armstrong,Manuel Ruíz Borrego,Rinat Yerushalmi,François P. Duhoux,Toshimi Takano,Wenjun Lü,C. Livings,Anton Egorov,S-B Kim
出处
期刊:ESMO open [Elsevier BV]
卷期号:8 (1): 101375-101375 被引量:3
标识
DOI:10.1016/j.esmoop.2023.101375
摘要

In DESTINY-Breast02 (NCT03523585), T-DXd improved progression-free and overall survival vs TPC in pts with HER2+ mBC who were resistant/refractory to trastuzumab emtansine (T-DM1) (Krop et al. SABCS 2022). Here, we report data on PROs and health-related quality of life (QoL). Pts with HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization amplified) T-DM1–resistant/refractory mBC were assigned 2:1 to T-DXd or TPC (trastuzumab + capecitabine or lapatinib + capecitabine). PROs were collected and measured at prespecified timepoints using the European Organization for Research and Treatment of Cancer QoL questionnaires (EORTC QLQ)-C30, the breast-cancer–specific EORTC QLQ-BR45 (scored as EORTC QLQ-BR23), and the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analog scale. Change from baseline (CFB) and time to definitive deterioration (TDD) were assessed. QLQ-C30 global health status (GHS)/QoL score was the primary variable of interest. In the T-DXd (n = 406) and TPC (n = 202) arms (median treatment duration of the safety analysis set: 11.3 vs ∼4.5 mo), questionnaire compliance was >92% at baseline and >76% at cycles 3-29. Mean CFB of GHS/QoL remained stable (within ±10 points) up to cycle 39 for T-DXd and cycle 21 for TPC, after which the number of pts on treatment was not informative (n < 10%). Median TDD was longer with T-DXd vs TPC for GHS/QoL (14.1 vs 5.9 mo; HR, 0.56 [95% CI, 0.44-0.71]) and for all measured QLQ-C30 subscales, including physical functioning (18.7 vs 6.8 mo; HR, 0.46 [95% CI, 0.36-0.60]) and pain (18.7 vs 5.8 mo; HR, 0.38 [95% CI, 0.29-0.49]), with the exception of nausea/vomiting (5.7 vs 6.1 mo; HR, 1.09 [95% CI, 0.86-1.39]). With T-DXd vs TPC, pts experienced prolonged TDD on the QLQ-BR23 arm symptom subscale (18.3 vs 8.8 mo; HR, 0.57 [95% CI, 0.44-0.75]). Mean CFB in GHS/QoL suggested that overall health and QoL were maintained in T-DXd-treated pts. TDD was longer on all measured QLQ-C30 subscales, except for nausea/vomiting, for pts receiving T-DXd vs TPC. These results continue to support the benefit of T-DXd in pts with T-DM1–resistant HER2+ mBC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zex发布了新的文献求助20
刚刚
fantasy的应助被Parker采纳,获得10
刚刚
刚刚
2秒前
莫断痕发布了新的文献求助10
2秒前
2秒前
尊敬的灰狼完成签到 ,获得积分10
3秒前
3秒前
3秒前
4秒前
fghgg发布了新的文献求助30
4秒前
HQ发布了新的文献求助10
4秒前
杨媛发布了新的文献求助20
5秒前
平贝花发布了新的文献求助10
5秒前
华仔的应助被儒雅从安采纳,获得10
5秒前
5秒前
格物致知完成签到,获得积分10
7秒前
7秒前
7秒前
8秒前
8秒前
搜集达人的应助被iFaceDOG采纳,获得10
8秒前
77完成签到,获得积分20
9秒前
00粥发布了新的文献求助10
9秒前
res完成签到,获得积分10
9秒前
云隐发布了新的文献求助10
9秒前
小马甲的应助被1234采纳,获得10
10秒前
刘刘发布了新的文献求助10
10秒前
lii完成签到,获得积分10
10秒前
11秒前
秋风的应助被yk采纳,获得10
11秒前
艺术人生发布了新的文献求助10
11秒前
YouHan完成签到,获得积分20
12秒前
华仔的应助被胡萝卜卜采纳,获得10
13秒前
13秒前
潘小康发布了新的文献求助10
13秒前
13秒前
ZZ发布了新的文献求助10
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194174
求助须知:如何正确求助?哪些是违规求助? 9580103
关于积分的说明 21869209
捐赠科研通 7793764
什么是DOI,文献DOI怎么找? 3437545
关于科研通互助平台的介绍 2560983
邀请新用户注册赠送积分活动 2484291